Published in Mol Cancer Ther on May 04, 2010
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol (2012) 1.69
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One (2012) 1.41
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes. PLoS One (2012) 1.13
Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther (2012) 1.10
Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One (2011) 1.08
The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One (2012) 1.04
A multivariate approach to the integration of multi-omics datasets. BMC Bioinformatics (2014) 1.01
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Res (2011) 1.00
A least angle regression model for the prediction of canonical and non-canonical miRNA-mRNA interactions. PLoS One (2012) 0.97
Computational prediction of intronic microRNA targets using host gene expression reveals novel regulatory mechanisms. PLoS One (2011) 0.96
miRNA target enrichment analysis reveals directly active miRNAs in health and disease. Nucleic Acids Res (2012) 0.96
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS One (2012) 0.95
Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. Proc Natl Acad Sci U S A (2014) 0.95
Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines. PLoS One (2012) 0.94
NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PLoS One (2014) 0.93
Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One (2011) 0.93
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res (2015) 0.92
Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties. BMC Syst Biol (2013) 0.90
Toward a combinatorial nature of microRNA regulation in human cells. Nucleic Acids Res (2012) 0.90
MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells. BMC Cancer (2013) 0.89
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet (2014) 0.89
Estimating the activity of transcription factors by the effect on their target genes. Bioinformatics (2014) 0.89
An appraisal of RECQ1 expression in cancer progression. Front Genet (2014) 0.88
Direct quantification of mRNA and miRNA from cell lysates using reverse transcription real time PCR: a multidimensional analysis of the performance of reagents and workflows. PLoS One (2013) 0.88
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS One (2014) 0.87
Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS One (2012) 0.86
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene (2016) 0.85
Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. PLoS One (2013) 0.84
USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase. Cell Death Differ (2013) 0.84
Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst) (2013) 0.84
Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines. BMC Syst Biol (2011) 0.84
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget (2015) 0.83
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget (2015) 0.82
MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons. Int J Mol Sci (2014) 0.81
Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage. Mol Cell Pharmacol (2011) 0.80
Large-scale modeling of condition-specific gene regulatory networks by information integration and inference. Nucleic Acids Res (2014) 0.80
Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. BMC Genomics (2014) 0.79
Feature selection and classifier performance on diverse bio- logical datasets. BMC Bioinformatics (2014) 0.79
Strategic applications of gene expression: from drug discovery/development to bedside. AAPS J (2013) 0.77
Brain cancer prognosis: independent validation of a clinical bioinformatics approach. J Clin Bioinforma (2012) 0.77
High-throughput RNA profiling via up-front sample parallelization. Nat Methods (2015) 0.77
MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer (2015) 0.76
Evaluation of O2PLS in Omics data integration. BMC Bioinformatics (2016) 0.76
Estimating genome-wide regulatory activity from multi-omics data sets using mathematical optimization. BMC Syst Biol (2017) 0.75
The NCI-60 Methylome and its Integration into CellMiner. Cancer Res (2016) 0.75
Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology. World J Clin Oncol (2015) 0.75
A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob DNA (2016) 0.75
A p-Median approach for predicting drug response in tumour cells. BMC Bioinformatics (2014) 0.75
Bioinformatics of Cancer ncRNA in High Throughput Sequencing: Present State and Challenges. Front Genet (2012) 0.75
Handling missing rows in multi-omics data integration: multiple imputation in multiple factor analysis framework. BMC Bioinformatics (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol (2009) 7.47
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res (2004) 6.98
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2006) 5.37
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res (2008) 4.14
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett (2005) 3.39
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Impact of normalization on miRNA microarray expression profiling. RNA (2009) 2.63
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 2.38
miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol (2007) 2.26
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther (2006) 1.73
MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res (2008) 1.69
Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J (2002) 1.63
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther (2008) 1.22
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol (2004) 1.18
Integromic analysis of the NCI-60 cancer cell lines. Breast Dis (2004) 1.08
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol (2006) 3.13
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res (2003) 2.50
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene (2004) 2.36
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics (2012) 1.71
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) (2003) 1.70
Drug discovery: Cell lines battle cancer. Nature (2012) 1.70
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet (2010) 1.66
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
TCPA: a resource for cancer functional proteomics data. Nat Methods (2013) 1.64
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res (2003) 1.54
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res (2010) 1.53
HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem (2009) 1.53
Quality assessment of microarrays: visualization of spatial artifacts and quantitation of regional biases. BMC Bioinformatics (2005) 1.52